This is Weave

Weave is re-shaping drug development with AI, evolving the way therapeutic knowledge is maintained, applied, and communicated.

Meet the Co-founders

Brandon Rice

Brandon Rice

Chief Executive Officer

Ari Caroline

Ari Caroline

Chief Strategy Officer

At Weave, our customers set the standard for regulatory knowledge management.

Our AI-native platform supports the entire regulatory knowledge lifecycle, from initial planning and content reuse through authoring, review, submission, and post-submission response.

The stakes in this work are exceptionally high: patients’ lives and well-being on one hand, the billions of dollars required to bring a drug to market on the other. We built Weave to equip human experts with the AI tools they need to meet that scrutiny.

Scientists, engineers, and regulatory experts founded Weave, with leading investors and organizations across the life sciences placing their trust in it. Together, we’re helping teams move faster, work smarter, and focus on the science that matters most.

Schedule a demo

Our Strategic Advisory Board

Russ Altman, M.D., Ph.D.

Stanford University

Tala Fakhouri, Ph.D., M.P.H.

Parexel

Stewart Hen

Serrado Capital

Sean Khozin, M.D., M.P.H.

CEO Roundtable on Cancer

Chris Lee, M.P.H.

Gilead Sciences

Vada Perkins, Ph.D.

Boehringer Ingelheim

Andrew S. Robertson, Ph.D., JD

Denali Therapeutics

Our investors

From Seed to Scale

  1. 2024

    Seed Funding Round

  2. 2024

    Submission Builder Launched

  3. 2025

    Series A Funding

  4. 2025

    HAQ Manager Launched

  5. 2026

    Announced Collaboration with Takeda